These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 36965526)
1. Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation. Dichtl S; Diem G; Jäger M; Zaderer V; Lupoli G; Dächert C; Muenchhoff M; Graf A; Blum H; Keppler OT; Lass-Flörl C; Weiss G; Wilflingseder D; Posch W Antiviral Res; 2023 May; 213():105581. PubMed ID: 36965526 [TBL] [Abstract][Full Text] [Related]
2. Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections. Dichtl S; Zaderer V; Kozubowski V; Abd El Halim H; Lafon E; Lanser L; Weiss G; Lass-Flörl C; Wilflingseder D; Posch W Front Med (Lausanne); 2022; 9():1005589. PubMed ID: 36250084 [TBL] [Abstract][Full Text] [Related]
3. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O Nat Commun; 2023 Feb; 14(1):824. PubMed ID: 36788246 [TBL] [Abstract][Full Text] [Related]
4. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld. Zhao Q; Wang X; Zhang Z; Liu X; Wang P; Cao J; Liang Q; Qu J; Zhou M J Med Virol; 2023 Jul; 95(7):e28932. PubMed ID: 37403923 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants. Cho J; Shin Y; Yang JS; Kim JW; Kim KC; Lee JY Antiviral Res; 2023 Jun; 214():105609. PubMed ID: 37086978 [TBL] [Abstract][Full Text] [Related]
10. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies. Planas D; Bruel T; Staropoli I; Guivel-Benhassine F; Porrot F; Maes P; Grzelak L; Prot M; Mougari S; Planchais C; Puech J; Saliba M; Sahraoui R; Fémy F; Morel N; Dufloo J; Sanjuán R; Mouquet H; André E; Hocqueloux L; Simon-Loriere E; Veyer D; Prazuck T; Péré H; Schwartz O bioRxiv; 2022 Nov; ():. PubMed ID: 36415455 [TBL] [Abstract][Full Text] [Related]
11. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Uraki R; Kiso M; Iida S; Imai M; Takashita E; Kuroda M; Halfmann PJ; Loeber S; Maemura T; Yamayoshi S; Fujisaki S; Wang Z; Ito M; Ujie M; Iwatsuki-Horimoto K; Furusawa Y; Wright R; Chong Z; Ozono S; Yasuhara A; Ueki H; Sakai-Tagawa Y; Li R; Liu Y; Larson D; Koga M; Tsutsumi T; Adachi E; Saito M; Yamamoto S; Hagihara M; Mitamura K; Sato T; Hojo M; Hattori SI; Maeda K; Valdez R; ; Okuda M; Murakami J; Duong C; Godbole S; Douek DC; Maeda K; Watanabe S; Gordon A; Ohmagari N; Yotsuyanagi H; Diamond MS; Hasegawa H; Mitsuya H; Suzuki T; Kawaoka Y Nature; 2022 Jul; 607(7917):119-127. PubMed ID: 35576972 [TBL] [Abstract][Full Text] [Related]
12. Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. Tao K; Tzou PL; Kosakovsky Pond SL; Ioannidis JPA; Shafer RW Microbiol Spectr; 2022 Aug; 10(4):e0092622. PubMed ID: 35700134 [TBL] [Abstract][Full Text] [Related]
13. Genotypic and predicted phenotypic analysis of SARS-COV-2 Omicron subvariants in immunocompromised patients with COVID-19 following tixagevimab-cilgavimab prophylaxis. Ordaya EE; Vergidis P; Razonable RR; Yao JD; Beam E J Clin Virol; 2023 Mar; 160():105382. PubMed ID: 36731147 [TBL] [Abstract][Full Text] [Related]
14. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156 [TBL] [Abstract][Full Text] [Related]